The Lynx Group
Cholangiocarcinoma News

TreeTopp: Randomized Phase 2 Study of Varlitinib plus Capecitabine versus Placebo in Second-Line Advanced or Metastatic BTC

Web Exclusives — May 28, 2020

Varlitinib is a reversible small-molecule pan human epidermal growth factor receptor (HER) inhibitor with low nanomolar potency against HER1 (EGFR), HER2, and HER4.

TreeTopp1 was a global, multicenter, double-blind, phase 2 study in which patients with biliary tract cancer (BTC) who progressed after first-line therapy that included ≥6 doses of gemcitabine, with radiographically measurable disease based on RECIST v1.1, ECOG PS 0 or 1, and albumin ≥3 g/dL. The patients were randomized (1:1) to varlitinib (V) (300 mg twice daily) plus capecitabine (C) (1000 mg/m2 twice daily 14 days on/7 days off) (V + C) or placebo plus capecitabine (P + C). The dual primary end points were objective response rate (ORR) and progression-free survival (PFS), defined as the time from randomization to radiologic progression assessed by independent central review. Secondary end points included overall survival (OS).

A total of 127 patients were randomized (V + C, n = 64; P + C, n = 63). The odds ratio for ORR with V + C versus P + C was 2.278 (9.4% vs 4.8%; P = .42), the hazard ratio (HR) for PFS for V + C versus P + C was 0.90 (median PFS, 2.8 vs 2.8 months; P = .63), and the HR for OS for P + C versus V + C was 1.11 (median OS, 7.8 vs 7.5 months; P = .66). Although not powered to evaluate subgroup interactions, in a subgroup analysis, V + C showed PFS benefit versus P + C in 2 subgroups: gallbladder cancer (HR, 0.55), median PFS (2.9 vs 1.6 months); and females (HR, 0.59), median PFS, 4.1 versus 2.8 months. There was no PFS benefit for V + C versus P + C among males and non-gallbladder cancer patients. Toxicities were generally balanced between arms apart from a slightly higher incidence of hyperbilirubinemia, diarrhea, and fatigue in the V + C versus P + C arm. Grade 3/4 toxicities were reported in 66% and 59% of patients in the V + C and P + C arms, respectively.

Based on the interim data as of July 15, 2019, the authors concluded that although there was no benefit for V + C for ORR, PFS, or OS versus P + C in second-line advanced BTC, subgroup analysis suggested that patients with gallbladder cancer and female patients achieved a comparatively higher median PFS with V + C versus P + C. ClinicalTrials.gov number NCT03093870.

Reference

  1. Javle M, et al. ASCO 2020. Abstract 4597.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: